3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Sarcoma
6
Pancreatic Neoplasms
6
Neoplasm Metastasis
6
Colorectal Neoplasms
5
Ovarian Neoplasms
4
Breast Neoplasms
4
Sarcoma, Ewing
3
Neoplasms
3
Insulin-Like Growth Factor I, Resistance To
3
Carcinoma, Non-Small-Cell Lung
3
Rectal Neoplasms
2
Lymphoma
2
Colonic Neoplasms
2
Carcinoid Tumor
2
Adenocarcinoma
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Effusion, Malignant
1
Pathologic Complete Response
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroectodermal Tumors, Primitive
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Gemcitabine
5
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
selpercatinib
2
niraparib
2
napabucasin
2
entinostat
2
Ocoxin
2
Irinotecan
2
Bevacizumab
2
temsirolimus
1
tariquidar
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
irinotecan sucrosofate
1
ganitumab
1
Valproic Acid
1
Trabectedin
1
Taxes
1
Sunitinib
1
Sirolimus
1
Psilocybin
1
Paclitaxel
1
Oxaliplatin
1
Leucovorin
1
Immunoglobulin G
1
Fluorouracil
1
Etoposide
1
Disulfides
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Endocrine Gland Neoplasms
×
ganitumab
×
Clear all
NCT01231347
2024-07-16
GAMMA
NantCell, Inc.
Phase 3
Completed
800 enrolled
11 charts